Searchable abstracts of presentations at key conferences in endocrinology

ea0075p16 | Pituitary and neuroendocrinology | EYES2021

Rarest of them all: A case of chronic lymphocytic leukaemia mimicking pituitary adenoma

S Balakrishnan , A Krishnan , S Shaw , N Saravanappa , J Ayuk , B Jose

65-year-old lady presents to GP with 3-month history of fatigue, weight loss and nausea with background of stable Chronic Lymphocytic Leukaemia (CLL). GP started Levothyroxine 25 mg OD due to low T4 of 5.9 pmol/l (12-22) and low TSH of 0.25 mU/l (0.27-4.2). As she continued to feel tired, random cortisol was requested which was low at 25nmol/l leading to admission. Admission cortisol was 55nmol/l with an inappropriately normal ACTH of 11.6 ng/l (7.2-63.3). Pituitary profile sh...

ea0044p135 | Neoplasia, cancer and late effects | SFEBES2016

The effect of peptide receptor radionuclide therapy (PRRT) on symptoms and tumour burden in patients with metastatic neuroendocrine tumour (NET)

Abraham Stalin , Casey Ruth , Challis Ben , Pitfield Deborah , Whitley S , Shaw Ashley , Heard Sarah , Saad Zia , Buscombe John , Simpson Helen

Peptide receptor radionuclide therapy (PRRT) is a targeted therapy using synthetic somatostatin analogues attached to a radionuclide, which binds to tumours expressing somatostatin receptors. The aim was to review the role of PRRT in a tertiary referral centre. We retrospectively reviewed a cohort of 25 patients (eight males, 17 females), with a median age of 65, who received Yttrium-90 DOTATATE or Lutetium-177 DOTATATE at Addenbrookes Hospital. The location of the primary tum...